Clinical and Economic Burden of COPD in Patients on Inhaled Triple Therapy in Germany – A Retrospective Claims Data Analysis
A substantial proportion of COPD patients initiating TT experience exacerbations resulting in high resource utilization and costs for the healthcare system. With poor treatment adherence and rare use of guideline-recommended escalation therapies, effective new treatments are needed to address the unmet medical need in this patient population.
Authors
- Oliver Damm (ORCID: https://orcid.org/0000-0003-0261-3655)
- Marie Schild (ORCID: https://orcid.org/0000-0001-9583-9228)
- Roland Buhl (ORCID: https://orcid.org/0009-0001-5695-5899)
- Lena Richter (ORCID: https://orcid.org/0009-0007-0996-3005)
- Claus Franz Vogelmeier (ORCID: https://orcid.org/0000-0002-9798-2527)
- Joanna Diesing (ORCID: https://orcid.org/0000-0001-5809-583X)
- Nils Kossack (ORCID: https://orcid.org/0000-0002-9521-3898)
- Anna C. Meyer (ORCID: https://orcid.org/0000-0003-2749-7179)
- Denis Azabdaftari
- Timm Greulich
- Inka Albrecht (ORCID: https://orcid.org/0009-0006-6384-662X)
Institutions
- Philipps University of Marburg (DE)
- Johannes Gutenberg University Mainz (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Sanofi (Germany) (DE)
- IGES Institut (DE)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/copd.s550636
- Citations
- 1
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Sanofi
- Regeneron Pharmaceuticals